Cisneros DF

Language: Spanish
References: 11
Page: 73-81
PDF size: 168.87 Kb.

ABSTRACT

Sodium fluoride was one of the first anabolic bone drugs, its action on the osteoblasts was well demonstrated, but it just works on the cancellus bone. However, on the cortical bone it retards the mineralization process, so it is not indicated in patients with osteoporosis because it increases the fracture risk. Parathyroid hormone family peptides helps both, cancellous bone and cortical bone formation, but it should be managed very carefully in patients with urolithiasis, cancer in the bones, and Paget’s disease. No often that its main action is on cancellous bone, it also improves the cortical. Strontium ralenate is another anabolic bone that stimulates osteogenesis and also it has been reported that inhibits the action of osteoclasts, reason why it is inferred that decouples favorably the turnover in patients with osteoporosis. Side effects are mild, but one disadvantage is its high cost.

REFERENCES

1. Pak CY, Zerwekh JE, et al. Slow release sodium fluoride in osteoporosis. J Bone Min Res 1996; 11(5): 561-564.

2. Riggs BL, Hodgson SF, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322 (12): 802-809.

3. Riggs LH, OFollon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 1994; 9(2): 265-275.

4. Riggs BL, et al. The role of the sodium fluoride in the treatment of osteoporosis; in Clinical Disorders of Bone and Mineral Metabolism. Henry Ford joint and Bone Speciality Center, Detroit, 1988.

5. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010; 17(1): 25-54.

6. Neer RM, Arnaud CD, et al. Effect of parathyroid hormona (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-1441.

7. IV International Simposium on Osteoporosis. Hong Kong, 1993.

8. Reginster JY, Felsenberg D, et al. Effects of long term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum 2008; 58(6): 1687-1695.

9. Reginster JY, et al. Strontium ranelate, 8 years efficacy on vertebral and non-vertebral fractures in postmenopausal osteoporotic women. Osteoporos Int 2008; 19 (suppl 1): S131-S132.

10. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350(5): 459-468.

11. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium Ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90(5): 2816-2822.